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Phenotypic Changes in Artemisinin-Resistant Plasmodium falciparum
Lines In Vitro: Evidence for Decreased Sensitivity to Dormancy and
Growth Inhibition
Franka Teuscher,a,b Nanhua Chen,a Dennis E. Kyle,c Michelle L. Gatton,b and Qin Chenga,b
Drug Resistance and Diagnostics, Australian Army Malaria Institute, Brisbane, Australiaa; Malaria Drug Resistance and Chemotherapy Laboratory, Queensland Institute of
Medical Research, Brisbane, Australiab; and Department of Global Health, College of Public Health, University of South Florida, Tampa, Florida, USAc
The appearance of Plasmodium falciparum parasites with decreased in vivo sensitivity but no measurable in vitro resistance to
artemisinin has raised the urgent need to characterize the artemisinin resistance phenotype. Changes in the temporary growth
arrest (dormancy) profile of parasites may be one aspect of this phenotype. In this study, we investigated the link between dor-
mancy and resistance, using artelinic acid (AL)-resistant parasites. Our results demonstrate that the AL resistance phenotype has
(i) decreased sensitivity of mature-stage parasites, (ii) decreased sensitivity of the ring stage to the induction of dormancy, and
(iii) a faster recovery from dormancy.
Artemisinin combination therapy (ACT) is the cornerstone ofmalaria control programs. However, reports of parasites in
Cambodia with decreased in vivo sensitivity to artemisinin (ART)
(4, 6) have raised serious concerns about the emergence of arte-
misinin resistance in the field. To gain insight into the mecha-
nisms of ART resistance and to monitor its spread (5), it is critical
to characterize the resistance phenotype. To date, it has not been
well described, and no molecular marker has been identified.
Clinical data from western Cambodia indicated that parasite
clearance times after artesunate monotherapy were significantly
longer than those in northwestern Thailand (4). However, few
other phenotypic changes were identified. The Thai and Cambo-
dian isolates showed no significant differences in susceptibility
(50% inhibitory concentrations [IC50s]) to either dihydroarte-
misinin (DHA) or artesunate in classic in vitro drug susceptibility
tests (4).
Reduced susceptibility of ring-stage parasites to ART has been
proposed as an explanation for the prolonged clearance times ob-
served in Cambodia (4, 7). This hypothesis would explain the
results of conventional in vitro susceptibility tests, which assess
the effect of a drug on thematuration of parasites from the ring to
the schizont stage (4), and may be supported by an in vitro study
showing that only ring-stage artemisinin-adapted parasites per-
sisted during 48 h of drug pressure (10). In contrast, it has been
reported that IC50s for three laboratory parasite lines adapted to
tolerate 80 ng/ml of artelinic acid (AL) increased 2- to 5-fold (1).
These changes were accompanied by increases in copy number,
mRNA expression, and protein expression of the pfmdr1 gene.
Using one of these adapted parasite lines, increases in IC50 of up to
12-fold after renewed drug selection were reported (2). The with-
drawal of drug pressure resulted in deamplification of the pfmdr1-
containing amplicon and in partial reversal of resistance to AL.
Another feature of Plasmodium falciparum parasites is their
ability to enter a quiescent state (dormancy) following exposure to
ART, where development of ring-stage parasites is temporarily
arrested. ART-sensitive parasites can stay dormant for up to 20
days after a single exposure to DHA in vitro, with 0.044% to
1.313% of parasites recovering, depending on the drug dose and
parasite strain (8). This phenomenon could explain the high fre-
quency of recurrences in the field (3, 9). Changes in dormancy
patterns may also be involved in ART resistance and may explain
the discrepancy between the clinical response phenotype and in
vitro susceptibility results of field isolates. For instance, it has been
reported that dormancy recovery appears to be more rapid for in
vitro drug-selected parasites than for sensitive parasites (10).
Here we describe the phenotype of AL-resistant P. falciparum
laboratory lines for which a decrease in parasite susceptibility has
been shown previously (1, 2). We compared the dormancy prop-
erties of these AL-adapted parasites and their sensitive parent lines
post-drug treatment at a range of different concentrations. More-
over, we monitored the growth characteristics of parasites under
continuous drug pressure.
MATERIALS AND METHODS
Preparation of parasites in vitro. AL-sensitive P. falciparum lines W2,
D6, and TM91C235 were cultivated as previously described (8). Frozen
stocks of AL-resistant lines W2AL80, D6AL80, and TM91C235AL80 (1)
were thawed and reexposed to several cycles of treatment with 80 ng/ml
AL (2 to 5 continuous days per round). Before the start of each experi-
ment, parasites were synchronized at the ring stage by two rounds of
sorbitol treatment.
Comparing the effects of AL on the growth of sensitive and resistant
parasite lines. Ring-stage parasites of AL-sensitive and -resistant lines
were placed into two preprepared drug-filled 96-well plates to a final vol-
ume of 200l (2% parasitemia; 3% hematocrit). The plates contained AL
at doubling dilutions from 10 to 640 ng/ml. One plate was harvested after
30 h of incubation, and thin and thick smears were made from each well.
Giemsa-stained thin smears were examined by light microscopy to assess
the proportions of parasites at various developmental stages. The second
plate was incubated for 24 h before the wells were washed with fresh
medium and the drug was reapplied and incubated for a further 48 h.
Received 4 August 2011 Returned for modification 29 August 2011
Accepted 30 September 2011
Published ahead of print 10 October 2011
Address correspondence to Qin Cheng, qin.cheng@defence.gov.au.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.05456-11
428 aac.asm.org 0066-4804/12/$12.00 Antimicrobial Agents and Chemotherapy p. 428–431
 o
n
 January 3, 2012 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
After this 72-hour exposure, the plate was washed, resuspended in drug-
free medium, and incubated for an additional 48 h. After further washes,
cultures were diluted 1:20 in fresh medium, and parasite growth in each
well was quantified by measuring the amount of cellular HRP2, using an
SD malaria antigen P.f enzyme-linked immunosorbent assay (ELISA) kit
(Standard Diagnostics Inc., South Korea) following the manufacturer’s
instructions. Drug-free cultures were run in parallel to all experiments as
positive controls. We defined the growth inhibition threshold as the low-
est concentrationwhich caused a50%reduction in parasite growth after
72 h of continuous drug pressure relative to the positive control.
Comparing the induction of and recovery from dormancy of AL-
sensitive (W2) and -resistant (W2AL80) parasites.Twenty-milliliter cul-
tures of ring-stage parasiteswith an initial parasitemia of 2%were exposed
to a range of AL concentrations (for W2, 640 to 5,120 ng/ml; and for
W2AL80, 2,560 to 10,240 ng/ml) for 6 h, after which cultures were washed
with fresh medium and returned to the incubator. Cultures were passed
through a magnetic column (25 MACS CS separation column; Miltenyi
Biotec) on 3 consecutive days, starting 24 h after treatment (8), to remove
mature parasites (possibly unaffected by the drug). Cultures were then
maintained until parasitemias reached 10%. Sham-treated parasites
(without drug and magnetic column treatment) were used as a control.
Blood films were made daily, stained with Giemsa stain, and examined by
light microscopy to determine parasitemia. The presence of dormant
ring-stage parasites was also examined at 24 h posttreatment.
RESULTS
AL-resistant lines grow and multiply at higher concentra-
tions of AL than sensitive lines. Based on ELISA results, the AL
growth inhibition thresholds for the sensitive lines were 10 ng/ml
for W2 and 40 ng/ml for D6 and TM91C235. For the resistant
lines, the growth inhibition threshold was 2-fold higher for
TM91C235AL80 (80 ng/ml), 4-fold higher for D6AL80 (160 ng/
ml), and 16-fold higher for W2AL80 (160 ng/ml). These thresh-
olds were consistent when a biological replicate was conducted.
Examination of blood smears taken after 30 h of drug exposure
showed a dramatic difference in parasite maturation under drug
pressure (Fig. 1A and B). For the resistant line W2AL80, more
than 80%of the initial ring-stage parasitesmatured to the tropho-
zoite or schizont stagewhen exposed to 40 ng/ml or less of AL (Fig.
1A), and 640 ng/ml of AL was required to almost completely stop
parasite maturation. In contrast, fewer than 20% of AL-sensitive
ring-stage parasites progressed to mature stages when exposed to
only 10 ng/ml of AL; development was completely halted at AL
concentrations above 10 ng/ml (Fig. 1A). The same trend was
observed for the D6 and TM91C235 parent and resistant lines
(data not shown). The quantity ofHRP2 inW2AL80 after the 72-h
drug incubation was 2.9- to 5.8-fold higher than in its sensitive
parent at drug concentrations of40 ng/ml (data not shown). In
contrast, the ratio of HRP2 quantity in W2AL80 at the highest
drug concentration (640 ng/ml) and inW2 in the no-drug control
were 1.02 and 1.04. Combined, these results demonstrate that the
AL-resistant parasite lines were able tomature andmultiply in the
presence of AL.
AL-resistant W2AL80 requires a higher drug concentration
to induce dormancy than AL-sensitive W2. Following 30 h of
incubation under drug pressure at concentrations ranging from
10 to 640 ng/ml AL, the proportions of dormant and dead rings
among W2 and W2AL80 parasites were compared. For the pur-
poses of this study, the dormant and dead ring-stage parasites
were grouped together and are referred to as dormant henceforth
because they could not always be differentiated by means of mor-
phology. In W2 samples, 48% of parasites were dormant ring-
stage parasites following 10 ng/ml exposure to AL. This figure
increased to 86% at AL concentrations of 20 ng/ml and above
(Fig. 1A). In contrast, only 45%of parasites were dormant rings in
W2AL80 samples at 320 ng/ml of AL, a 32-fold increase in drug
concentration compared to that withW2. At AL concentrations of
40 ng/ml, only a small proportion of dormant rings (4.3%)
were observed in the resistant line (Fig. 1A).
W2AL80 recovers from dormancy earlier thanW2. To assess
howW2AL80 andW2parasites recover after a 6-h exposure toAL,
parasite cultures were monitored daily from day 4. Recovery data
from days 1 to 3 are not available because the cultures were passed
through a magnetic column on these days to ensure that growing
parasites, which were possibly unaffected by the drug, were re-
moved. Dormant ring-stage parasites could be observed on mi-
croscope slides at 24 h posttreatment at all drug concentrations.
The AL concentrations used in this experiment were 64 to 512 and
16 to 64 times higher than the growth inhibition thresholds deter-
mined above from the 72-h exposure period forW2 andW2AL80,
respectively. In the W2 cultures exposed to 640, 2,560, and 5,120
ng/mlAL, parasitemia remained below 1%until day 8. After day 8,
parasitemia started to increase, with 10% parasitemia reached
FIG 1 Proportions and morphologies of various parasite developmental
stages after 30 h of continuous AL exposure. (A) Proportions of parasites at
various developmental stages after 30 h of continuous AL exposure at concen-
trations ranging from 10 to 640 ng/ml for W2 and W2AL80. Cultures are
labeled by parasite line followed by drug concentration. (B) Light microscopic
pictures (thick smears) of W2 and W2AL80 parasites 30 h after continuous
treatment with 80 ng/ml AL. (a) W2 control; (b) W2AL80 control; (c) W2
posttreatment; (d) W2AL80 posttreatment. Arrows point to typical dormant
parasites.
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on day 12 for the 640-ng/ml AL-exposed cultures and on day 15
for the 2,560- and 5,120-ng/ml AL-exposed cultures (Fig. 2). In
contrast, the W2AL80 cultures reached levels of 10% on day 8
after exposure to 2,560 ng/ml AL and on day 9 after AL exposures
of 5,120 ng/ml and 10,240 ng/ml. Hence, all cultures recovered
following exposure to 640 ng/ml AL, with W2AL80 recovering
faster thanW2 for a comparable effective drug concentration (rel-
ative to the growth inhibition threshold). The sham-treated cul-
tures for bothW2 andW2AL80 reached 10%parasitemia within 4
days (Fig. 2).
DISCUSSION
Parasites with decreased in vivo sensitivity to artemisinin have
been reported, but in vitro these isolates did not appear signifi-
cantly more resistant than those obtained elsewhere (4). The aim
of this study was to define the resistance phenotype by character-
izing the growth and dormancy recovery profiles of well-
developed and -characterized AL-resistant parasite lines com-
pared with their drug-sensitive parents. We used AL-resistant
lines because these were the only available lines that had been well
demonstrated to be resistant to ART derivatives and because there
is a close structural relationship between AL and other ART deriv-
atives, so similar phenotypes can be expected. P. falciparum para-
site lines W2AL80, D6AL80, and TM91C235, used in this study,
had been adapted to and were able to grow for at least 20 days
under a drug pressure of 80 ng/ml AL. These parasites had shown
relative increases in AL IC50 of up to 12-fold, suggesting true re-
sistance (1, 2). Although these laboratory resistant lines may not
be able to reflect all characteristics of the wild-type isolates, inves-
tigating their characteristics provides insights into the possible
phenotypic and genotypic changes of ART-resistant parasites in
the field.
In this study, at least 160 ng/ml of AL for 72 h was required to
reduce parasite growth by 50% in the resistant line W2AL80. Ex-
amination of blood smears taken after 30 h under the same exper-
imental conditions confirmed parasite maturation into schizont
stages at concentrations up to 80 ng/ml AL, demonstrating not
only that ring-stage parasites were able to develop into mature
stages but also that trophozoites were able to develop through to
schizonts. This contrasts with the results of Witkowski et al. (10),
who observed no mature parasite stages during a 48-hour ART
exposure of F32-ART, a laboratory line that had been adapted to
survive 24-h drug cycles of up to 9 M ART (2,560 ng/ml). At
this stage, it is not clear how our in vitro observations compare
morphologically to parasites posttreatment in patients with ade-
quate or long parasite clearance times.
A small proportion (12.3%) of dormant and dead ring-stage
parasites could be observed in the resistant parasite line following
30 h of continuous exposure to the drug concentration to which
the parasites had been adapted. However, this proportion was not
significantly different from that of the sham-treated control sam-
ples. Only at concentrations above 80 ng/ml did this proportion
increase, reaching45% at 320 ng/ml. This is in sharp contrast to
the case forW2, where 48% of parasites were dormant at 10 ng/ml
of AL. These results indicate that dormancy still occurs in the
resistant parasite line but that higher drug concentrations are re-
quired to induce it. The majority of resistant parasites do not
develop dormancy at concentrations they can tolerate. This also
suggests that dormancy may be an innate mechanism that para-
sites use to survive drug concentrations which would otherwise
cause severe damage and that it is triggered only when parasite
development is significantly inhibited.
To monitor recovery from dormancy, we exposed W2 and
W2AL80 to concentrations well above the IC50 for 6 h. At these
high concentrations, dormant ring-stage parasites could be ob-
served onmicroscope slides at 24 h posttreatment at all drug con-
centrations. The use of a magnetic column on 3 consecutive days
ensured removal of any parasites that might not have gone into
dormancy. AL-resistant parasites recovered from dormancy after
treatment with concentrations as high as 10,240 ng/ml. Recovery
occurred significantly earlier in W2AL80 than in W2 following
exposure to a comparable effective drug concentration. These re-
sults are consistent with earlier findings which also showed de-
layed recovery in sensitive lines compared to ART-resistant lines
in vitro (10).
In summary, AL-adapted parasites show resistance to AL at all
developmental stages. Exposure to AL can induce dormancy in
resistant ring-stage parasites, but much higher drug concentra-
tions are required to induce this arrest. Recovery from dormancy
occurs at a higher rate than that of the AL-sensitive parent line,
although it is not possible from this study to determine if this is
due to an earlier resumption of normal growth or a larger propor-
tion of parasites recovering from dormancy.
These results indicate thatART-induceddormancyandresistance
are linked in the 3AL-resistant lines we studied. At this stage, it is not
clear how these findings relate to the delayed clearance observed in
field isolates. Based on our observations, we hypothesize that the first
step toward thedevelopmentofARTresistance is thedevelopmentof
resistance in the ring stages,whichreduces theproportionofparasites
entering a dormant state. The second stage of resistance is resistance
in mature-stage parasites, which allows the parasites to survive and
replicate in thepresenceofdrug.OurAL-resistantparasiteshavebeen
developed over years of repeated drug exposure, so they are likely to
be at a more advanced stage of resistance than the field isolates col-
lected in Cambodia. Therefore, decreased sensitivity in both ring
stages, i.e., changes in dormancy pattern, andmature stages is prom-
inent in these laboratory lines. In contrast, field isolatesmay be in the
first stage of resistance, where only changes in the sensitivity of ring
stages have developed, which enables them to bypass dormancy and
develop into trophozoites. Since isolates have not entered the second
stage of resistance, trophozoites are still sensitive to and are killed by
ART.Thismay explain thedelayedparasite clearance following treat-
ment. Further studies using field isolates are needed to evaluate this
FIG 2 Dormancy recovery profiles of W2 and W2AL80 bulk cultures after
treatment with AL at various concentrations (ng/ml) for 6 h, with passage
through a magnetic column on days 1 to 3. Cultures are labeled according to
parasite line and AL exposure concentration.
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hypothesis. Understanding the phenotypic changes which occurred
in these resistantparasiteswill contribute to abetterunderstandingof
the resistancemechanisms involved sowe can develop tools tomon-
itor for and contain ART resistance.
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